The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...
Omvoh's approval provides a new treatment option for Crohn's disease patients, especially those unresponsive to existing therapies. The FDA granted approval to Eli Lilly and Company’s ...
The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...
It is available only through a restricted REMS program. The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults ...
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...
NEW YORK (WPIX) – The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday. Spravato is a first-of-its-kind medication to ...
The U.S. Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray as a standalone therapy for adults with treatment-resistant depression. The spray, Spravato ...
calls for the FDA to entirely withdraw the drug’s approval. President Donald Trump, however, has been inconsistent, saying that he doesn’t plan to block access to the abortion pills while ...
The Princeton University Board of Trustees has approved the appointment of two new assistant professors to the faculty. Aviram Uri, in physics, joins the faculty in September 2025. Uri, who ...
Be sure to come back regularly for the latest updates. Currently, the drug's FDA-approved loading regimen features three doses given 14 days apart, plus a fourth dose 30 days after the third.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback